非血缘脐血移植治疗难治复发成人急性白血病的疗效分析
回顾性分析22例难治复发成人急性白血病患者接受非血缘脐血移植挽救治疗的临床资料,采用清髓性预处理和环孢素A/短程霉酚酸酯预防GVHD。初步结果显示移植后42天髓系累积植入率95.5%,2年无病生存率和总生存率分别为53.7%和58.1%,移植相关死亡率22.7%。
要点
- 22例难治复发成人急性白血病患者接受非血缘脐血移植挽救治疗。
- 移植后42天髓系累积植入率95.5%,120天血小板累积植入率81.8%。
- 2年累积无病生存率53.7%,总生存率58.1%,累积复发率18.7%。
核心结论
- 初步结果显示,对于常规化疗无效的难治复发成人急性白血病患者,采用非血缘脐血移植安全、有效。
研究设计与样本
- 回顾性分析2009年11月至2017年5月22例行非血缘脐血移植挽救治疗的难治复发成人急性白血病患者的临床资料。
- 全部患者采用清髓性预处理方案,均采用环孢素A/短程霉酚酸酯方案预防GVHD。
主要发现
- 22例患者中男9例,女13例,中位年龄23(15~44)岁,中位体重52.5(43~82)kg。
- 回输脐血有核细胞中位数为3.07(1.71~5.30)×10^7/kg(受者体重),CD34+细胞中位数为1.60(0.63~3.04)×10^5/kg(受者体重)。
- 移植后42天髓系累积植入率为95.5%(95%CI 45.2%~99.7%),中位植入时间19(13~27)天。
- 移植后120天血小板累积植入率为81.8%(95%CI 54.2%~93.6%),中位植入时间42(20~164)天。
- Ⅱ~Ⅳ度、Ⅲ~Ⅳ度急性GVHD发生率分别为36.4%、13.6%,慢性GVHD 2年累积发生率为40.3%;移植后180天移植相关死亡率为22.7%;2年累积复发率为18.7%(95%CI 3.6%~42.5%),2年累积无病生存率及累积总生存率分别为53.7%和58.1%。
临床怎么用
- 作者认为,对于常规化疗无效的难治复发成人急性白血病患者,采用非血缘脐血移植安全、有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the clinical efficacy and safety of unrelated umbilical cord blood transplantation (UCBT) in the treatment of refractory and relapsed acute leukemia (AL) patients. Methods: The clinical data of 22 refractory and relapsed AL patients who were treated with UCBT as salvage therapy from November 2009 to May 2017 were retrospectively analyzed. All patients received a myeloablative conditioning regimen for prevention of graft-versus-host disease (GVHD) with cyclosporine A (CSA)/short course of mycophenolate mofetil (MMF). Results: ①Of 22 patients, 9 cases were male and 13 female. The median age was 23 (15-44) years and median weight of 52.5 (43-82) kg. All patients were transplanted with a median umbilical cord blood nucleated cells of 3.07 (1.71-5.30)×107/kg (by weight), the median CD34+ cells was 1.60 (0.63-3.04)×105/kg (by weight). ②The myeloid cumulative implantation rate was 95.5% (95%CI 45.2-99.7%) after transplantation of 42 d, with the median implantation time of 19 (13-27) d. The platelet cumulative implantation rate after transplantation of 120 d was 81.8% (95%CI 54.2-93.6%), the median implantation time of 42 (20-164) d. ③The incidence of Ⅱ-Ⅳ, Ⅲ-Ⅳ aGVHD and the 2 year cumulative incidence of cGVHD were 36.4%, 13.6% and 40.3% respectively. ④ The transplant related mortality (TRM) after transplantation of 180d was 22.7%, 2 year cumulative rate of relapse was 18.7% (95%CI 3.6-42.5%), 2 year disease-free survival rate (DFS) and overall survival rate (OS) were 53.7% and 58.1%, respectively. Conclusion: The preliminary results show that the use of UCBT is safe and effective for refractory and relapsed AL patients who fail to respond to conventional chemotherapy. 目的: 探讨非血缘脐血移植(UCBT)挽救治疗难治复发急性白血病(AL)患者的临床疗效和安全性。 方法: 回顾性分析2009年11月至2017年5月22例行UCBT挽救治疗的难治复发成人AL患者的临床资料,全部患者采用清髓性预处理方案,均采用环孢素A/短程霉酚酸酯方案预防GVHD。 结果: ①22例患者中男9例,女13例,中位年龄23(15~44)岁;中位体重52.5(43~82)kg。所有患者回输脐血有核细胞中位数为3.07(1.71~5.30)×107/kg(受者体重),CD34+细胞中位数为1.60(0.63~3.04)×105/kg(受者体重)。②移植后42 d髓系累积植入率为95.5%(95%CI 45.2%~99.7%),中位植入时间为19(13~27)d;移植后120 d血小板累积植入率为81.8%(95%CI 54.2%~93.6%),中位植入时间为42(20~164)d。③Ⅱ~Ⅳ度、Ⅲ~Ⅳ度急性GVHD发生率以及慢性GVHD 2年累积发生率分别为36.4%、13.6%和40.3%。④移植后180 d移植相关死亡率为22.7%;2年累积复发率为18.7%(95%CI 3.6%~42.5%),2年累积无病生存率及累积总生存率分别为53.7%和58.1%。 结论: 对于常规化疗无效的难治复发成人AL患者,初步结果显示采用UCBT安全、有效。.
引用
- Chu XD, Chen EL, Zhu XY, et al. [Efficacy analysis of unrelated cord blood transplantation in the treatment of refractory and relapsed adult acute leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29562443. doi:10.3760/cma.j.issn.0253-2727.2018.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。